Revolutionary Treatment for Keratoconus:
Introducing CTAK by CorneaGen
June 4, 2024
David Hutton
Revolutionary Treatment for Keratoconus: Introducing CTAK by CorneaGen
CorneaGen has recently introduced an innovative treatment option for keratoconus called Corneal Tissue Addition for Keratoplasty (CTAK). This breakthrough solution aims to enhance corneal contouring specifically for keratoconic eyes, providing a significant advancement in keratoconus management.
About CTAK
CTAK was developed in collaboration with CTAK LLC and Ziemer. It features patient-ready, gamma-irradiated sterile corneal tissue segments that are non-immunogenic. These tissue segments are laser cut and custom-designed to match the specific cone severity and location of each patient’s keratoconus. This customization ensures a tailored approach to treatment, optimizing outcomes for patients.
Advantages of CTAK
One of the key benefits of CTAK is its ability to save time in the operating room while maximizing the use of corneal donations. Bernie Iliakis, president and CEO of CorneaGen, expressed the company’s excitement about the potential of CTAK to transform the lives of keratoconus patients. “We have a long history as innovators and tissue processing leaders. CTAK represents a true treatment advancement while honoring and maximizing the gift of corneal donation,” Iliakis stated.
Immediate Vision Improvements
Dr. William Wiley, medical director at the Cleveland Eye Clinic Division of Midwest Vision Partners, highlighted the immediate positive effects of the CTAK procedure. Patients often experience significant improvements in both best corrected and uncorrected vision right after the surgery. “This immediate improvement at the first follow-up is an exciting experience for those dealing with keratoconus,” Dr. Wiley noted.
Innovative Collaboration
The development of CTAK is a result of the collaborative efforts of CorneaGen and its partners. The co-inventors of CTAK, including Dr. Peter S. Hersh, Dr. Steven Greenstein, and Dr. John Gelles, have played a pivotal role in advancing this treatment. Dr. Hersh emphasized the transformative impact of working with innovative partners like CorneaGen and Ziemer. “We’re able to improve patient vision, reducing the recovery time and risk compared to a corneal transplant,” he added.
CorneaGen’s Commitment to Eye Health
Beyond product and tissue processing innovations, CorneaGen is deeply involved in patient advocacy, supporting tens of thousands of patients annually. In 2023 alone, CorneaGen provided more than 32,500 sight-restoring grafts and partnered with over 25 eye, organ, and tissue banks to meet the corneal transplant needs in the U.S. and nearly 50 other countries worldwide.
The launch of CTAK by CorneaGen marks a significant milestone in the treatment of keratoconus. With its customized approach and immediate vision improvement, CTAK is set to revolutionize how keratoconus is managed, offering new hope to patients around the globe.
At Keratoconus Specialists of Maryland, we are renowned for our advanced keratoconus treatments and personalized care. With over 40 years of combined experience, our expert eye doctors leverage cutting-edge technologies and tailored treatment plans to address the unique challenges of keratoconus. Our commitment to excellence and patient-focused approach ensures that each individual receives the highest level of eye care, helping them achieve clear and comfortable vision.
Schedule a Consultation Today
Contact our office today to learn about the keratoconus treatments and see if it’s the right option for you. We offer personalized consultations with Dr. Azman, a leading keratoconus specialist, to discuss your unique needs and determine the proper treatments to regain clear vision and a better quality of life.
Don’t let keratoconus control your life. Take the first step towards seeing clearly again.
